ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2692

Vitamin D Deficiency in Systemic Sclerosis Patients: Relations with Multiple Clinical Parameters and Standard Treatment

Amelia Chiara Trombetta1, Vanessa Smith2, Emanuele Gotelli1, Massimo Ghio1, Sabrina Paolino1, Carmen Pizzorni3, Amber Vanhaecke4, Barbara Ruaro5, Alberto Sulli3 and Maurizio Cutolo3, 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy, 2Faculty of Internal Medicine, Ghent University, Ghent, Belgium, 3Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Policlinico San Martino, University of Genoa, Genoa, Italy, Genoa, Italy, 4Department of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, Gent, Belgium, 5Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy, Genoa, Italy

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: complications, systemic sclerosis and treatment, Vitamin D

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Vitamin D Deficiency In Systemic Sclerosis Patients:

 Relations With Multiple Clinical Parameters and Standard Treatment

Background/Purpose : In SSc patients, low 25-hydroxyvitamin D (25(OH)D) serum concentrations have been shown [1]. Primary aim of the study was to evaluate possible correlations between 25(OH)D serum levels and multiple clinical parameters, in patients with systemic sclerosis (SSc). Secondary aim was the evaluation of the effectiveness of standard vitamin D replacement therapy.

Methods: 154 SSc patients were recruited in all seasons of the year. 25(OH)D serum concentrations were evaluated using LIAISON 25-OH system (Diasorin, Italy). In addition, MedsgerÕs disease severity scale (DSS), nailfold video capillaroscopy (NVC) and all examinations covered by the international guidelines were evaluated [2]. Treatments assumption, including oral colecalciferol, was considered. Non-parametric tests were used for statistical analysis.

Results: 25(OH)D mean serum concentration was 18.7 ±9 ng/ml (<20 classified as a deficiency). A statistically significant correlation was found with presence/absence of fibrotic abnormalities at lung CT scan (16.1 ±8 ng/ml and 20 ±10 ng/ml respectively, p= 0.04) (Figure 1A). DSS parameters correlating with serum concentrations of 25(OH)D were: peripheral vascular (p= 0.03), kidney (p= 0.02), gastrointestinal (p= 0.05) (Figure 1B, 1C, 1D). No significant correlation was observed with digital ulcers incidence, which was closely related to NVC patterns (p<0.0001).

As expected, a statistically significant difference was observed between 25(OH)D serum concentrations in different seasons (winter: 14.6 ±7.8 ng/ml, spring: 17.2 ±7.9 ng/ml, summer: 21.43 ±10 ng/ml, autumn: 20.2 ±10 ng/ml, p= 0.032) (Figure 1E).

No effect of oral colecalciferol (1000 UI per day for at least 6 months) was observed on serum 25(OH)D both in treated (18.8 ±10 ng/ml) or untreated patients (18.7 ±9 ng/ml,  p= 0.81) (Figure 1F).

Conclusion: 25(OH)D deficiency correlated with advanced lung involvement and peripheral vascular system, kidney, and gastrointestinal tract involvement (according to the  MedsgerÕs DSS). Supplementation with standard doses of oral colecalciferol was not effective in increasing serum concentrations of 25(OH)D. Therefore, for substitutive therapy, higher doses of colecalciferol should be evaluated [3].

References. [1] Cutolo M et al. Nat Rev. Rheumatol 2010; 6: 578-87; [2] Medsger TA Jr et al. J Rheumatol 1999; 26: 2159-67; [3] Tangpricha V et al. J Clin Endocrinol Metab 2012; 97: 1082-93.


Disclosure: A. C. Trombetta, None; V. Smith, None; E. Gotelli, None; M. Ghio, None; S. Paolino, None; C. Pizzorni, None; A. Vanhaecke, None; B. Ruaro, None; A. Sulli, None; M. Cutolo, None.

To cite this abstract in AMA style:

Trombetta AC, Smith V, Gotelli E, Ghio M, Paolino S, Pizzorni C, Vanhaecke A, Ruaro B, Sulli A, Cutolo M. Vitamin D Deficiency in Systemic Sclerosis Patients: Relations with Multiple Clinical Parameters and Standard Treatment [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/vitamin-d-deficiency-in-systemic-sclerosis-patients-relations-with-multiple-clinical-parameters-and-standard-treatment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vitamin-d-deficiency-in-systemic-sclerosis-patients-relations-with-multiple-clinical-parameters-and-standard-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology